Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV001547606 | SCV001767354 | likely benign | not provided | 2020-08-05 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001547606 | SCV002283956 | uncertain significance | not provided | 2022-11-15 | criteria provided, single submitter | clinical testing | ClinVar contains an entry for this variant (Variation ID: 1187982). This variant has not been reported in the literature in individuals affected with DIAPH3-related conditions. This variant is present in population databases (rs200231889, gnomAD 0.04%). This sequence change replaces arginine, which is basic and polar, with glutamine, which is neutral and polar, at codon 603 of the DIAPH3 protein (p.Arg603Gln). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV004039283 | SCV004857613 | uncertain significance | not specified | 2024-04-26 | criteria provided, single submitter | clinical testing | The c.1808G>A (p.R603Q) alteration is located in exon 16 (coding exon 16) of the DIAPH3 gene. This alteration results from a G to A substitution at nucleotide position 1808, causing the arginine (R) at amino acid position 603 to be replaced by a glutamine (Q). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |